Cost-effectiveness of five different anti-tumour necrosis factor tapering strategies in rheumatoid arthritis: a modelling study

Scandinavian Journal of Rheumatology ◽

10.1080/03009742.2019.1613674 ◽

2019 ◽

Vol 48 (6) ◽

pp. 439-447 ◽

Author(s):

LM Verhoef ◽

DPG Bos ◽

CHM van den Ende ◽

FHJ van den Hoogen ◽

B Fautrel ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Necrosis Factor ◽

Modelling Study

Download Full-text

Cost Effectiveness of Tumour Necrosis Factor-?? Inhibitors as First-Line Agents in Rheumatoid Arthritis

PharmacoEconomics ◽

10.2165/00019053-200624120-00006 ◽

2006 ◽

Vol 24 (12) ◽

pp. 1221-1232 ◽

Author(s):

James R Spalding ◽

Joel Hay

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Inhibitors ◽

Necrosis Factor

Download Full-text

PMS34 AN EXPLORATORY EVALUATION OF THE COST-EFFECTIVENESS OF RITUXIMAB AND ABATACEPT IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO A TUMOUR NECROSIS FACTOR INHIBITOR IN CANADA

Value in Health ◽

10.1016/s1098-3015(10)73410-0 ◽

2009 ◽

Vol 12 (3) ◽

pp. A70

Author(s):

S Yunger ◽

B Mistry

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Inhibitor ◽

Inadequate Response ◽

Severe Rheumatoid Arthritis ◽

Factor Inhibitor ◽

The Cost ◽

Necrosis Factor

Download Full-text

Tumour Necrosis Factor-a and Heat-Shock Protein 70-2 Gene Polymorphisms in a Family with Rheumatoid Arthritis

Acta Microbiologica et Immunologica Hungarica ◽

10.1556/amicr.51.2004.3.4 ◽

2004 ◽

Vol 51 (3) ◽

pp. 263-269 ◽

Author(s):

A. Balog ◽

J. Gál ◽

Zsófia Gyulai ◽

Szilvia Zsilák ◽

Yvette Mándi

Keyword(s):

Rheumatoid Arthritis ◽

Heat Shock Protein ◽

Tumour Necrosis Factor ◽

Heat Shock Protein 70 ◽

Gene Polymorphisms ◽

Tumour Necrosis ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1104777.560749 ◽

2008 ◽

Author(s):

Geoff Littlejohn

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Population Based ◽

Population Based Study ◽

Tumour Necrosis Factor Inhibitors ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1108991.565450 ◽

2008 ◽

Author(s):

Martin Aringer ◽

Alexander Kleymann

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Joint Damage ◽

Tumour Necrosis Factor Inhibitor ◽

Inadequate Response ◽

Structural Joint ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Successful resolution of pneumonia developed in a patient affected by Crohn’s disease, rheumatoid arthritis, myasthenia gravis and recurrent uveitis during concomitant treatment with tumour necrosis factor α inhibitors and conventional immunosuppressive drugs

Rheumatology International ◽

10.1007/s00296-009-1012-6 ◽

2009 ◽

Vol 30 (7) ◽

pp. 977-978 ◽

Author(s):

Erika Angelucci ◽

Monica Cesarini ◽

Piero Vernia

Keyword(s):

Rheumatoid Arthritis ◽

Myasthenia Gravis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Immunosuppressive Drugs ◽

Concomitant Treatment ◽

Tumour Necrosis Factor Α ◽

Successful Resolution ◽

Factor Α ◽

Necrosis Factor

Download Full-text

Immediate treatment with tumour necrosis factor inhibitors in synthetic disease-modifying anti-rheumatic drugs-naïve patients with rheumatoid arthritis: results of a modified Italian Expert Consensus

Rheumatology ◽

10.1093/rheumatology/key076 ◽

2018 ◽

Vol 57 (Supplement_7) ◽

pp. vii32-vii41

Author(s):

Alessandra Bortoluzzi ◽

Guido Valesini ◽

Salvatore D’Angelo ◽

Bruno Frediani ◽

Laura Bazzichi ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Expert Consensus ◽

Tumour Necrosis Factor Inhibitors ◽

Disease Modifying ◽

Necrosis Factor

Download Full-text

FLOW CYTOMETRICAL DETERMINATION OF INTERLEUKIN 1β, INTERLEUKIN 6 AND TUMOUR NECROSIS FACTOR α IN MONOCYTES OF RHEUMATOID ARTHRITIS PATIENTS; RELATION WITH PARAMETERS OF OSTEOPOROSIS

Cytokine ◽

10.1006/cyto.1998.0500 ◽

1999 ◽

Vol 11 (11) ◽

pp. 869-874 ◽

Author(s):

Ann Verbruggen ◽

Luc S De Clerck ◽

Chris H Bridts ◽

Jan F Van Offel ◽

Wim J Stevens

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Interleukin 6 ◽

Tumour Necrosis ◽

Interleukin 1Β ◽

Tumour Necrosis Factor Α ◽

Factor Α ◽

Necrosis Factor

Download Full-text

FRI0059 The efficacy and safety of pegylated recombinant methionyl human soluble tumour necrosis factor receptor type i (peg stnf-ri; p55) in a randomised, placebo-controlled, clinical study of patients with rheumatoid arthritis (ra)

10.1136/annrheumdis-2001.1188 ◽

2001 ◽

Author(s):

M Schiff ◽

D Furst ◽

R Fleischmann ◽

M Macri ◽

T Joh ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Study ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Receptor Type ◽

Tumour Necrosis Factor Receptor ◽

Type I ◽

Efficacy And Safety ◽

Controlled Clinical Study ◽

Necrosis Factor

Download Full-text

The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis

Annals of the Rheumatic Diseases ◽

10.1136/ard.2008.088138 ◽

2008 ◽

Vol 67 (8) ◽

pp. 1174-1177 ◽

Author(s):

E J M Toonen ◽

M J H Coenen ◽

W Kievit ◽

J Fransen ◽

A M Eijsbouts ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Disease Severity ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Receptor ◽

Adalimumab Treatment ◽

Necrosis Factor

Download Full-text